All new opportunities will be placed in the front portion of the report. Current opportunities that have not yet reached their deadline will follow. Please note that all funding opportunities are subject to change without notice. Opportunities are listed in order of deadline date.

NEW OPPORTUNITIES – WEEK OF MAY 5, 2017

**Familial RUNX Grant Program: Familial RUNX1 Research Grant**
**Sponsor:** Alex's Lemonade Stand Foundation for Childhood Cancer
**Deadline:** June 1, 2017

“Alex's Lemonade Stand Foundation (ALSF) is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloblastic leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML. ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around familial RUNX1 disorders. Purpose of the grant is to fund research that will develop strategies leading to the development of therapies for the prevention of the transition from pre-leukemia to leukemia for patients with the familial RUNX1 disorder. Project More…”


**Psychosocial Grant Program: Psychosocial Family Impact Grants**
**Sponsor:** Alex's Lemonade Stand Foundation for Childhood Cancer
**Deadline:** June 9, 2017

“ALSF is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Psychosocial Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact. The Psychosocial: Family Impact Grants will support studies by established investigators that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact.”


**Psychosocial Grant Program: Psychosocial Launch Grants**
**Sponsor:** Alex's Lemonade Stand Foundation for Childhood Cancer
**Deadline:** June 9, 2017

“ALSF is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Psychosocial Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact. The Psychosocial: Launch Grants will support studies by early career researchers that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. Demonstration of outstanding mentorship and a career plan that shows commitment to pediatric cancer investigation are important components of a successful application.”


**SWOG Early Exploration and Development (SEED) Fund**
**Sponsor:** The Hope Foundation
**Deadline:** July 1, 2017

“SWOG’s mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain extramural funding More…”

Intensive Longitudinal Analysis of Health behaviors: leveraging New Technologies to Understand Health Behaviors (U24)

**Sponsor:** US Department of Health and Human Services; NIH  
**Deadline:** September 25, 2017

“This FOA invites applications to establish a Research Coordinating Center (RCC) to facilitate and support the Intensive Longitudinal Health Behaviors Initiative. The goal of this initiative is to support collaborative research projects studying factors that influence key health behaviors at the individual level, using intensive longitudinal data collection and analytic methods, as well as to further advance research through the broad dissemination of data with the research community, as appropriate. The network will also assess how study results can be leveraged to introduce innovations into longstanding behavioral theories to advance the field of theory-driven behavior change interventions. The RCC will coordinate common activities of the network including communications, meetings, governance, and the development of methods harmonization, data integration, and dissemination. Components of Participating Organizations: OBSSR; NCI”


Investigator Sponsored Research (ISR)

**Sponsor:** Gilead Sciences, Inc./Gilead Sciences Pty Ltd.  
**Deadline:** Continuous

“Gilead welcomes funding requests for innovative, high-impact projects that relate to at least one of five core therapeutic areas: HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. The staff of Gilead are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world. Gilead actively supports investigator-sponsored research conducted by third parties on Gilead's marketed products or within therapeutic areas of interest to the company. This research can provide valuable information regarding the safety, efficacy, pharmacology, and tolerability of Gilead's products and supplement the comprehensive data generated in registration studies. More…”


Samuel Waxman Cancer Research Foundation (SWCRF) Grants

**Sponsor:** Samuel Waxman Cancer Research Foundation  
**Deadline:** Varies

“The SWCRF provides grants to institutions to fund novel research to better understand the causes of cancer and reprogramming cancer cells. The SWCRF seeks to build upon its scientific programs in the form of an Institute Without Walls. These grants are restricted to those investigators who are pursuing novel therapies to reverse the abnormal growth and differentiation of the cancer cell.

The SWCRF offers two different kinds of competitive grant awards:  
- Individual Grants that may be renewable for up to three years  
- Collaborative Grant to groups of multi-site, multi-disciplinary investigators

The goal of this two-tiered structure is to cultivate Individual Grantees to become members of a broader, international collaboration of scientists who may harness their collective resources to expedite the pace, breadth, and quality of research. For the past few years, the SWCRF payline has remained steady at approximately 12%, which is nearly twice the rate of the National Cancer Institute, despite the SWCRF’s continued increase in applications.”

**CONTINUING OPPORTUNITIES**

**Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01) (UG3/UH3)**

**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** May 9, 2017

“This purpose of this FOA is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.


**Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33)**

**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** May 10, 2017

“This FOA is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology. Specifically, this FOA targets the following four areas designated as scientific priorities: - Enhanced experimental and analytical capabilities addressing complexities of cancer development; - New capabilities advancing precise clinical diagnosis of cancer patients; - Novel predictive ex vivo and/or in silico modeling approaches; and - New technologies/approaches to improve biospecimen and data quality.

Applications must be focused on one of these areas and must be based on comprehensive preliminary data substantiating the potential of the proposed technologies/tools/capabilities and the functionality their contributing components. Essential aspect is a rigorous technical validation to ensure that the transformative, enabling potential of the proposed technologies/tools/capabilities for cancer research and/or clinical care is thoroughly verified by the end of the project period.”


**Lane Adams Quality of Life Award**

**Sponsor:** American Cancer Society  
**Deadline:** May 12, 2017

“The Award promotes improved quality of life for all persons with cancer and their families through public recognition of exemplary individuals who practice compassionate, skilled cancer care and who extend the warm hand of service. Finalists will be selected on the basis of leadership, innovation and excellence. The Award is unique in its focus on caregiving as opposed to accomplishments in academic achievement, research, volunteerism or advocacy. Winners are selected based on their history of caregiving that exceeds expectations for a person in that particular job or role. The Committee reserves this national recognition for those unique caregivers who lead in their areas of expertise and make a significant More…”


**Community Relations Grants**

**Sponsor:** Sanofi; Genzyme Corporation  
**Deadline:** May 15, 2017

“Sanofi Genzyme also provides Community Relations funding to support non-profit organizations focused on science education, health/access to health care, and unmet community needs, specifically in and around the areas in the U.S. where Sanofi Genzyme has a business presence. Community Relations contributions are only available to certified non-profit organizations, and for specific programs and initiatives, not for general operating expenses or capital campaigns. The priority is to create sustainable partnerships that can have lasting impact, often by funding the same groups for different programs and initiatives over multiple years.”

AACR Scientific Achievement Awards – AACR Distinguished Lecture on the Science of Cancer Health Disparities, Funded by Susan G. Komen  
Sponsor: AACR  
**Deadline: May 17, 2017**  
“The lecture will recognize an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of cancer health disparities.”  

**Bioengineering Research Partnerships (U01)**  
Sponsor: US Department of Health and Human Services; NIH  
**Deadline: May 18, 2017**  
“This FOA encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 - 10 years. Components of Participating Organizations: NIBIB; NCI.”  

**Center for Coordination of Analytics, Science, Enhancement and Logistics (CASEL) in Tobacco Regulatory Science (U54)**  
Sponsor: NIH; FDA; ODP; NIDA; CTP  
**Deadline: LOI May 19, 2017**  
“This FOA solicits applications for a Center for CASEL in Tobacco Regulatory Science. CASEL will support the scientific research programs funded by the Food and Drug Administration (FDA) Center for Tobacco Products (CTP), and will facilitate synthesis, coordination and communications of research and career enhancement within those programs. The overall objective of CASEL is to support research programs that can inform the FDA CTP in tobacco product regulatory activities and actions. Through leadership, coordination, and facilitation of collaborative efforts, CASEL can accelerate the advancement of science relevant to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The NIH and the FDA have formed an interagency partnership to foster research relevant to FDA's tobacco regulatory authorities. The award under this FOA will be administered by the NIH using designated funds from the FDA CTP for tobacco regulatory science mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.”  

**Neoantigen-Based Therapeutic Targeting of Head and Neck Cancers**  
Sponsor: NIH; National Institute of Dental and Craniofacial Research  
**Deadline: LOI May 19, 2017**  
“The purpose of this FOA is to support basic and preclinical research aimed at developing novel immunotherapeutic targets for head and neck cancers (HNC), including salivary gland cancers. Research supported by this FOA will identify human HNC-specific neoantigens, and will test the utility of these neoantigens as targets for eliciting anti-tumor immune responses in affected patient populations.”  

**Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)**  
Sponsor: NIH; FDA; ODP; NCI; NHLBI; NIDA; NIEHS; CTP  
**Deadline: LOI May 19, 2017**  
“The purpose of this FOA is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.”  
**‘A’ Award**

**Sponsor:** Alex’s Lemonade Stand for Childhood Cancer  
**Deadline:** May 22, 2017

“ALSF’s mission is to raise money and awareness of childhood cancer causes, primarily for research into new treatments and cures, and to encourage and empower others, especially children, to get involved and make a difference for children with cancer. The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late translational studies. Preference will be given to...”


**Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01) (R21)**

**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** May 22, 2017

“The overarching objectives of this initiative are to understand the etiologic factors and the underlying mechanisms responsible for chronic liver diseases and documented cancer disparities among racial/ethnic minority and socioeconomic disadvantaged populations in the US. For the purpose of this initiative the focus is on the causes for increase in both the incidence and mortality rates of chronic liver disease and cancer among the health disparities populations. Many potential individual, contextual and structural factors influence health disparities; therefore, this...”


**Medical Research Grants: Reach Awards**

**Sponsor:** Alex's Lemonade Stand Foundation for Childhood Cancer  
**Deadline:** May 22, 2017

“ALSF's mission is to raise money and awareness of childhood cancer causes, primarily for research into new treatments and cures, and to encourage and empower others, especially children, to get involved and make a difference for children with cancer. In line with its mission, ALSF offers the ‘A’ Award as a four-year grant designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A career development plan must be included. More...”


**US Tobacco Control Policies to Reduce Health Disparities (R21) (R01)**

**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** May 24, 2017

“The purpose of this FOA is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment). Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics.


**Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01)**

**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** May 26, 2017

“This FOA encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the individual, team, healthcare system or community setting levels. Appropriate applications for this FOA should propose to intervene at one or more levels, and must measure outcomes at three or more levels, while accounting for interactions that occur between levels.”

Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure (R01)

Sponsor: US Department of Health and Human Services; NIH

Deadline: May 27, 2017

“The purpose of this FOA is to promote research on food specific molecular signatures and biomarkers of dietary consumption and to promote collaborative interactions among NIH and USDA supported nutrition researchers. Participating Organization(s): United States Department of Agriculture (USDA) Components of Participating Organizations: NIDDK; NCCAM; ODS; NIFA; NCI”


Research Answers to NCI’s Provocative Questions (R01) (R21)

Sponsor: NIH; NCI

Deadline: LOI May 28, 2017

“The purpose of this FOA is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that may now be open to investigations using new strategies and recent technical advances.

More…”


Revision Applications to NCI-Supported R01 Awards to Include Research on the NCI’s Provocative Questions (R01)
Revision Applications to NCI-Supported U01 Awards to Include Research on the NCI’s Provocative Questions (U01)
Revision Applications to NCI-Supported P01 Awards to Include Research on the NCI’s Provocative Questions (P01)
Revision Applications to NCI-Supported P-50 Awards to Include Research on the NCI’s Provocative Questions (P50)

Sponsor: NIH; NCI

Deadline: LOI May 28, 2017

“This FOA invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI’s Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.”


Perception and Cognition Research to Inform Cancer Image Interpretation (R01) (R21)

Sponsor: US Department of Health and Human Services; NIH

Deadline: May 30, 2017

“The purpose of this FOA is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. Components of Participating Organizations: NCI; NIBIB”


Independent Grants for Learning & Change (IGLC): Track 2 – Call for Grant Applications 9CGA – Advances in the Treatment of Renal Cell Carcinoma

Sponsor: Pfizer, Inc.

Deadline: May 31, 2017

“The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly. Through this CGA Pfizer encourages organizations to submit grant requests that, if funded will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer. Geographic Scope: North America; Europe Clinical Area: More…”

Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp)  
**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** June 1, 2017  
“The NCI hereby notifies Program Director(s)/Principal Investigator(s) holding eligible awards (as specified in this FOA) that funds are available for administrative supplements to prepare and deposit individual-level data from cancer epidemiology studies into NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.”  

Serious Adverse Drug Reaction Research (R21) (R01)  
**Sponsor:** US Department of Health and Human Services; NIH  
**Deadline:** June 1, 2017  
“The objective of this FOA is to encourage exploratory/developmental research projects addressing current gaps in our knowledge of serious ADRs, particularly those that are idiosyncratic. Exploratory and developmental research projects provide support for the early and conceptual stages of a project. These studies may involve considerable risk but may lead to a breakthrough in serious adverse drug reaction research, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on the field. The gaps to be addressed in the FOA exist along the translational spectrum. Potential areas of study include, but are not limited to, basic exploratory/developmental research into the immunologic, cellular, molecular, and toxicological mechanisms.”  

Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers  
**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** June 1, 2017  
“Through this FOA, the NCI invites applications for supplemental funding to eligible NCI awards so that involved personnel (awardees) can advance their efforts to gain needed knowledge on rare cancers. The goal is to support population-based, hypothesis-testing studies that will increase our understanding of the etiology or post-diagnosis outcomes of rare cancers.”  

Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp)  
**Sponsor:** US Department of Health and Human Services; NIH; NCI  
**Deadline:** June 1, 2017  
“The NCI announces an opportunity for awardees holding eligible NCI-funded awards to request administrative supplement funding to support augmented efforts to refine automated methodologies to obtain more accurate and reliable lifetime residential history data and linkages that would enhance cancer research.”  

NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01)  
**Sponsor:** US Department of Health and Human Services; NIH; NCCIH  
**Deadline:** June 2, 2017  
“This FOA invites cooperative agreement applications for investigator-initiated clinical trials of mind and body interventions in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a clinical trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention are critical for changes in outcome; assessing whether the intervention can be delivered with fidelity across trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention to be used in a future multi-site trial. It is important, therefore, to already have sufficient preliminary data that includes: demonstration of feasibility of recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; and evidence that the intervention has promise of clinical benefit. This FOA is not intended to support multi-site efficacy or effectiveness trials, nor will it support trials to test mind and body interventions for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.”  
Advancing the Science of Geriatric Palliative Care (R01) (R21)
Sponsor: NIA; NCCIH; NINR; NIMHD
Deadline: June 5, 2017
“This FOA encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.”

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)
Sponsor: US Department of Health and Human Services; NIH; NCI
Deadline: June 5, 2017
“This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.”

Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)
Sponsor: US Department of Health and Human Services; NIH; NCI
Deadline: June 5, 2017
“The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for collaborative R01 projects from multi-disciplinary teams to expand, improve, or transform the reliability and utility of mammalian cancer and tumor models for translational research. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address translational modeling research questions beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions. More…”

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)
Sponsor: US Department of Health and Human Services; NIH; NCI
Deadline: June 5, 2017
“Through this FOA, the NCI encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.”

Education and Health: New Frontiers (R01) (R21) (R03)
Sponsor: US Department of Health and Human Services; NIH
Deadline: June 5, 2017
“The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship. For this FOA, education refers to the comprehensive formal instruction that spans the human experience, from early childhood programs to pre-school, elementary and secondary schooling, college and adult learning programs. More…”
Reducing Overscreening for Breast, Cervical and Colorectal Cancers among Older Adults (R01) (R21)
Sponsor: US Department of Health and Human Services; NIH
Deadline: June 5, 2017
“The purpose of this FOA is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.”

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01) (R21)
Sponsor: US Department of Health and Human Services; NIH
Deadline: June 5, 2017
“This FOA invites cooperative agreement applications for investigator-initiated clinical trials of natural products to treat clinical symptoms such as those associated with sleep disturbance, pain conditions, or some mental health conditions (e.g., mild to moderate depression, anxiety, and post-traumatic stress), or examine the effects of probiotics and other natural products on gut-microbiome interactions with the brain and/or immune system. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable biological signature (i.e., measure of the mechanism of action), whenever it is possible or practical to measure and used by the patient population of interest. More...”

NCCIH Natural Product Phase II Clinical Trial Cooperative Agreement (U01)
Sponsor: US Department of Health and Human Services; NIH; NCCIH
Deadline: June 7, 2017
“This FOA invites cooperative agreement applications for investigator-initiated clinical trials of natural products on gut-microbiome interactions with the brain and/or immune system. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable biological signature (i.e., measure of the mechanism of action), whenever it is possible or practical to measure and used by the patient population of interest. More...”

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01) (R21)
Sponsor: US Department of Health and Human Services; NIH
Deadline: June 5, 2017
“This FOA encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data. Applications to this FOA are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. Components of Participating Organizations: NCI; NHGRI; NIDCR”

SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and prognostics Toward Commercialization (P44)
Sponsor: NIH, NCI
Deadline: LOI June 6, 2017
“This FOA solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-
funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.”


**NCI Transition Career Development Award (K22)**
Sponsor: US Department of Health and Human Services; NCI

**Deadline: June 12, 2017**

“This FOA represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.”


**Activities to promote Research Collaborations on Immune-Related Adverse Events (APRC-irAEs) Associated with Cancer Immunotherapy (Admin Supp)**
Sponsor: US Department of Health and Human Services; NIH

**Deadline: June 15, 2017**

“The overarching goal of this FOA is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise. Components of Participating Organizations: NCI; NIAID; NIAMS”


**APN and DNP Student Scholarship**
Sponsor: Oncology Nursing Society; Oncology Nursing Society Foundation

**Deadline: June 15, 2017**

“The purpose of this scholarship is: To provide financial support for students enrolled in an MSN or DNP program to accomplish work in areas of cancer prevention, care or control as outlined in the ONS Research Agenda; To provide a directed study approach to enable students to do capstone projects or theses in oncology, assisting them to accomplish educational program requirements; To advance evidence based practice in oncology care. Funding is intended to More...”


**Paul Calabresi Career Development Award for Clinical Oncology**
Sponsor: US Department of Health and Human Services; NCI

**Deadline: June 15, 2017**

“This FOA encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).”


**Exploratory/Developmental Clinical Research Grants in Obesity (R21)**
Sponsor: US Department of Health and Human Services; NIH

**Deadline: June 16, 2017**

“This FOA encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. Components of Participating Organizations: NIDDK; NCI Eunice Kennedy Shriver NICHD; ODS”

Resource Centers for Minority Aging (RCMAR) Coordinating Center (R24)
Sponsor: NIH; NIA
Deadline: June 20, 2017
“This FOA invites applications from qualified institutions to create or continue Resource Centers for Minority Aging Research (RCMAR) Coordinating Center (CC). The RCMAR Program aims to enhance the diversity of the aging research workforce by mentoring promising scientists from under-represented groups for sustained careers in aging research. RCMARs focus on priority areas of social, behavioral, and economic research on the processes of aging at the individual or societal level. The program supports research at multiple levels from genetics to cross-national comparative research, and at stages from basic through translational, with the goal to improve the health, well-being, function, and independence of older Americans. The new cycle of RCMARs will expand the scientific scope of the program to encourage transdisciplinary social and behavioral science research on any theme addressed in the National Institute on Aging Strategic Plan, and will include a new cohort of RCMARs focused on behavioral and social science related to Alzheimer's disease and related dementias (ADRD). Consistent with the longstanding focus of the RCMAR program on minority aging research, all centers are also expected to offer mentoring in health disparities and minority aging issues as a major component of their investigator development programs, thereby enhancing the potential impact of research supported by the program on all sectors of our aging society. The RCMAR CC will facilitate and coordinate trans-RCMAR activities. The CC will work closely with the NIA Program Officer and, in coordination with all RCMAR sites, be responsive to requests generated by key RCMAR site personnel, NIA, NIH, the scientific community, and the general public.”

Basic Cancer Research in Cancer Health Disparities (R01)
Sponsor: US Department of Health and Human Services; NIH; NCI
Deadline: June 19, 2017
“This FOA encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention intervention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.”

FWW Research Awards (Women’s Health Research Awards)
Sponsor: Foundation for Women’s Wellness
Deadline: June 20, 2017
“Only one application per applicant (i.e. Principal Investigator) may be submitted. The lead investigator must be an MD and/or PhD with faculty appointment of investigator, assistant professor or higher at an accredited U.S. academic institution or similar not-for-profit medical research institution.”

Resource Centers for Minority Aging Research (RCMAR) (P30)
Sponsor: NIH; NIA
Deadline: LOI June 20, 2017
“The National Institute on Aging (NIA) invites applications from qualified institutions for the creation or continuation of Resource Centers for Minority Aging Research (RCMARs). The primary purpose of this FOA is (1) to support centers that will enhance the diversity of the aging research workforce by mentoring promising scientists from under-represented groups for sustained careers in aging research in a selected area of scientific focus, and (2) to develop infrastructure to promote advances in this area and increase the number of researchers focused on the health and well-being of minority elders. RCMARs focus on priority areas of social, behavioral, and economic research on the processes of aging at the individual or societal level. The program supports research at multiple levels from genetics to cross-national comparative research, and at stages from basic through translational, with the goal to improve the health, well-being, function, and independence of older Americans. This new cycle of RCMARs will expand the scientific scope of the program to encourage transdisciplinary social and behavioral science research on any theme addressed in the National Institute on Aging Strategic Plan, consistent with the longstanding focus of the RCMAR program on minority aging research, all centers are also expected to offer mentoring in health disparities and minority aging issues as a major component of their research education programs, thereby enhancing the potential impact of research supported by the program on all sectors of our aging society.”
**FWW Fellowship Awards**
Sponsor: Foundation for Women's Wellness  
**Deadline: June 22, 2017**

“FWW’s Fellowship Awards recognize and support MD/PhD candidates or graduates pursuing fellowship or specialty training and working on research in women's health. This award goes directly to the individual awardee to acknowledge and support her/his academic, training and research success and pursuits.

Research should be related to FWW priority areas which are:
- Cardiovascular disease
- Leading female cancers
- Hormones’ role in disease and stage-of-life health concerns
- Diseases or health concerns that disproportionately afflict women
- Exploration of gender differences related to the aforementioned topics

FWW Fellowship Awards favor individuals with strong academic records and research/career indications of a commitment to research in a women’s health discipline. The awards include the: Gridley McKim-Smith Women's Health Fellowship Award; Krulewitz Women's Health Fellowship Award”


**Native American Research Centers for Health (NARCH) (S06)**  
Sponsor: US Department of Health and Human Services; NIH  
**Deadline: June 27. 2017**

“The purpose of this FOA is to encourage grant applications for new or continued NARCH. The NARCH program supports opportunities for conducting research and research training to meet the needs of American Indian/Alaska Native (AI/AN) communities. This FOA is issued by the National Institute of General Medical Sciences in conjunction with the other Institutes/Centers of the NIH and the Indian Health Service (IHS). Components of Participating Organizations: NIGMS; NCI”


**Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)**  
Sponsor: US Department of Health and Human Services; NIH; NCI  
**Deadline: June 28, 2017**

“This FOA is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the SPOREs, Cancer Centers and/or the NCI's National Clinical Trials Network.


**Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)**  
Sponsor: US Department of Health and Human Services; NIH; NCI  
**Deadline: June 30, 2017**

“The purpose of the Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07) is to support the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences.”


**Cellular Therapies for Treatment of Radiation Injuries (U01)**  
Sponsor: NIH; National Institute of Allergy and Infectious Diseases  
**Deadline: LOI July 1, 2017**

“The purpose of this FOA is to support studies to evaluate candidate cellular therapies to treat radiation-induced injuries in appropriate in vivo models when administered 24 hours or more post-irradiation. The research should be aimed toward the eventual approval of candidate cellular therapies under the United States Food and Drug Administration (FDA) Animal Rule licensure pathway.”

Dysregulation of Immune Cell Regulatory Pathways by Mtb in the Context of HIV Infection (R61/R33)
Sponsor: NIH; NIAID
**Deadline:** July 1, 2017

“The purpose of this FOA is to invite applications to support innovative preclinical research to identify *Mycobacterium tuberculosis* (Mtb)-mediated changes in key immune cell regulatory pathways in the context of HIV infection and evaluate strategies to reverse these changes to treat TB and TB/HIV infection, limit long-term disease associated tissue damage, and/or potentiate vaccine effectiveness.”


Familial RUNX1 Grant Program: Familial RUNX1 Patient Samples Grant
Sponsor: Alex’s Lemonade Stand Foundation for Childhood Cancer
**Deadline:** July 1, 2017

“ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorder leading to acute myeloid leukemia (FPD/AML) due to monoallelic germline RUNX1 mutations (OMIM:601399), with the ultimate goal of developing effective therapies to prevent the onset of AML. ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around FPD/AML. The purpose of the grant is to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. Projects should focus on leukemia caused by familial RUNX1 More...”


Lung Cancer Research Foundation Research Grants
Sponsor: Lung Cancer Research Foundation
**Deadline:** July 1, 2017

“The Lung Cancer Research Foundation is proud to fund research that they believe will make major contributions toward better treatments, screening, and prevention of lung cancer. The Foundation encourages applications for projects investigating a wide variety of research topics, including:

- Prevention and screening for early detection
- Identification of new biomarkers and the development of targeted therapies
- The development of next-generation chemotherapeutic agents
- Supportive measures for people with lung cancer and their families
- Quality of care and outcomes research”


Damon Runyon-Rachleff Innovation Award
Sponsor: Damon Runyon Cancer Research Foundation
**Deadline:** July 6, 2017

“The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the More...”


Pew Biomedical Scholars
Sponsor: Pew Charitable Trusts
**Deadline:** July 7, 2017

“The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level. Based on their performance during their education and training, candidates should demonstrate outstanding promise as contributors in science relevant to human health. Strong proposals will incorporate particularly creative and innovative approaches. Candidates whose work is based on biomedical principles, but brings in concepts and theories from more diverse fields, are encouraged to apply. Risk-taking is encouraged.”

Mechanisms and Consequences of Sleep Disparities in the US (R21)
Sponsor: US Department of Health and Human Services; NIH
Deadline: July 11, 2017
“The overall objective of this initiative is to support exploratory and developmental research to 1) understand the underlying social, cultural, environmental or biological factors contributing to sleep deficiencies among minority and health disparity populations and 2) how sleep deficiencies may lead to disparities in health outcomes. In addition, research on how quality of sleep and excess sleep affect health and how differences in sleep quality may lead to health disparities, is of interest. Many potential individual, contextual and structural factors influence health disparities; therefore, this initiative encourages applications that include multidisciplinary research to understand the interplay of multiple factors and mechanisms that explain sleep disparities. Successful projects will examine etiology of disparities in sleep deficiencies through a socioecological framework using multi-level determinants including individual, family/household, community, built environment, and healthcare factors. Studies for this initiative may include multi-disciplinary translational, behavioral, or epidemiological, or health services projects. In addition, projects can involve primary and/or secondary data collection.”

Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)
Sponsor: US Department of Health and Human Services; NIH; NCI
Deadline: July 14, 2017
“The purpose of this FOA is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.”

St. Baldrick's Infrastructure Grants
Sponsor: St. Baldrick’s Foundation
Deadline: July 14, 2017
“These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.”

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
Sponsor: US Department of Health and Human Services; FDA
Deadline: July 19, 2017
“The purpose of this FOA is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Components of Participating Organizations: Division of Program Coordination, Planning and Strategic Initiatives, ODP; NCI”

Centers for AIDS Research (P30)
Sponsor: US Department of Health and Human Services; NIH
Deadline: August 1, 2017
“The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. Components of Participating Organizations: NCI.”
Developmental Centers for AIDS Research (P30)
Sponsor: US Department of Health and Human Services; NIH
**Deadline: August 1, 2017**

“The purpose of this FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. Components of Participating Organizations: NCI.”


Meso Foundation Research Grant Program
Sponsor: Meso Foundation
**Deadline: August 5, 2017**

“The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. The Meso Foundation is the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. The Meso Foundation believes in a cure for meso. In addition to raising awareness of the disease, advocating on behalf of the meso community, educating those newly diagnosed and providing support to those affected, the Meso Foundation funds the most promising meso research projects through rigorous peer-review.”


Bayer Educational Grants
Sponsor: Bayer AG; Bayer USA Foundation
**Deadline: August 8, 2017**

“The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests: Healthcare professional education; Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.). Consideration for these programs may not be available for all therapeutic areas. Areas of Support:
- Dermatology
- Radiology
- Hematology-Hemophilia
- General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
- Neurology
- Women's Health Oncology:
  - Advanced Prostate Cancer
  - Colorectal Cancer
  - Gastrointestinal Stromal Tumor
  - Hepatocellular Carcinoma
  - Thyroid Cancer


Lasker Clinical Research Scholars Program (SI2/R00)
Sponsor: US Department of Health and Human Services; NIH
**Deadline: August 25, 2017**

“This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program. Components of Participating Organizations: NCI”

Novel Cell Non-autonomous Mechanisms of Aging (R01)
Sponsor: NIH; National Institute of Aging
Deadline: LOI September 3, 2017
“This FOA solicits applications on novel studies of cell non-autonomous mechanisms of aging. The goal of this FOA is to support applications that will lead to in-depth understanding of the mechanisms that produce cell non-autonomous aging signals: what they are, how they are generated from cell autonomous aging, how they are released from cells, how they are transported or communicated to other cells, and how they elicit aging upon reaching their target cells. Research supported by this FOA should lead to new insights and better understanding of the importance of cell non-autonomous mechanisms in aging at a tissue, system, or organismal level.”

Fanconi Anemia Research Fund Research Grants
Sponsor: Fanconi Anemia Research Fund
Deadline: LOI October 13, 2017
“The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities: To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia; To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders; To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure; To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life; To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.”

Diet and Physical Activity Assessment Methodology (R21)
Sponsor: US Department of Health and Human Services; NIH
Deadline: October 16, 2017
“This FOA encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. Components of Participating Organizations: NIDDK; NCI”

NIH Pathway to Independence Award (Parent K99/R00)
Sponsor: US Department of Health and Human Services; NIH
Deadline: October 16, 2017
“The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. Components of Participating Organizations: NCI”

Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76)
Sponsor: NIH; National Institute of Aging
Deadline: October 19, 2017
“This FOA invites early-stage physician and other health-professional investigators with a commitment to aging to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging is pursuing this initiative to recruit new investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.”
**Biophotonics**  
Sponsor: NSF, Directorate for Engineering, Division of Chemical, Bioengineering, Environmental and Transport Systems, Biomedical Engineering and Engineering Healthcare Cluster  
**Deadline: October 20, 2017**

“The goal of the Biophotonics program is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology. Fundamental engineering research and innovation in photonics is required to lay the foundations for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies. Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals. **More...**”

**Innovative Research in Cancer Nanotechnology (IRCN) (R01)**  
Sponsor: US Department of Health and Human Services; NIH; NCI  
**Deadline: November 21, 2017**

“This FOA encourages applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is a component of a broader program that is the NCI Alliance for Nanotechnology in Cancer. IRCN awards are designed to enable multidisciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. This scope includes research concerning the delivery of nanoparticles and/or nanodevices to desired and intended cancer targets in vivo and/or characterization of in vitro detection and diagnostic devices.”

**Graduate Medical Education (GME): Neuro-Oncology**  
Sponsor: US Department of Health and Human Services; NIH; NCI  
**Deadline: Continuous**

“The Neuro-Oncology fellowship program is designed to train academic Neuro-Oncologists and physician scientists across a range of medical subspecialties to be specialized in both clinical practice and/or research in Neuro-Oncology. It is a single, integrated clinical research fellowship training program in Neuro-Oncology between the Neuro-Oncology Branch (NOB), Center for Cancer Research (CCR), NCI and the Johns Hopkins University (JHU) School of Medicine Department of Oncology. The joint program is the NCI/JHU Neuro-Oncology Fellowship Training Program. Trainees may participate in the More...”

**Hearst Foundation Program Grants**  
Sponsor: Hearst Foundation  
**Deadline: Continuous**

“The Hearst Foundations support well-established nonprofit organizations that address important issues within its major areas of interests (education, health, culture, and social service), and that primarily serve large demographic or geographic constituencies. Within these areas, the foundations generally provide endowment, program, and capital grant support. Private nonprofits with significant support from the philanthropic community are favored over those financed through government sources. Health - The Hearst Foundations assist leading regional hospitals, medical centers and specialized medical institutions, such as children's and women's hospitals. More...”

**International Waldenstrom's Macroglobulinemia Foundation Research Grants**  
Sponsor: International Waldenstrom's Macroglobulinemia Foundation  
**Deadline: Varies**

“The IWMF supports the advancement of knowledge in the pathophysiological basis for the disease Waldenstrom's macroglobulinemia (WM). This goal is accomplished by providing research grants for basic biomedical research into the origins, clinical manifestations, treatments, and potential future cures for WM. At this time, the IWMF's research strategy supports the following areas: 1. Basic scientific research into the pathogenesis of WM. 2. Translational research to use new findings in basic biological research to develop new treatments for WM - from bench-to-bedside. 3. Exploratory research on promising new targets for the destruction of WM cells. 4. The development of representative WM cell lines. 5. The development of WM mouse models. 6. Meetings and conferences for researchers to encourage open communication and coordination of current research efforts. The majority of the IWMF's research funds are used for basic biomedical research grants; we do not fund clinical trials.”


**Keystone Symposia on Molecular and Cellular Biology Scholarships**
Sponsor: Keystone Symposia on Molecular and Cellular Biology

**Deadline:** Varies

“Keystone Symposia is offering scholarships to be used to help defray the expenses associated with conference attendance. Abstracts submitted for poster presentation will be used as the basis for awarding the scholarships. Scholarship recipients will be selected based on the quality of science of the abstract and the relevance of the abstract to the conference topic.”


**Kroger Company Foundation Grants**
Sponsor: Kroger Company Foundation

**Deadline:** Continuous

“The company's philanthropic objective is to enhance the quality of life in communities with a concentration of Kroger customers and employees. The Foundation was created to help the Company meet this goal. Here is a quick summary of eligible grant requests:

- Local United Way campaigns;
- Local educational organizations, primarily K-12 schools;
- Local hunger relief organizations;
- Local breast cancer and women’s health initiatives;
- Local organizations that support and promote the advancement of women and minorities;
- Local grassroots community organizations;
- Capital campaigns;
- Start up grants;
- and funding for special projects. Support will be provided only to programs that address a clearly identified need in the community and do so with clearly defined goals and objectives. The Foundation does not make grants to national or international programs.”


**Medical Education Grants**
Sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG/ Boehringer Ingelheim Pharmaceuticals, Inc.

**Deadline:** Continuous

“Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community. The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients.”


**Research Grants: Pediatric Low Grade Astrocytoma Foundation**
Sponsor: Pediatric Low Grade Astrocytoma Foundation

**Deadline:** Continuous

“The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors. Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.”


**Sanofi-Aventis Educational Grants**
Sponsor: Sanofi-Aventis US Inc.

**Deadline:** Continuous

“Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes. Purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited. Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.”

**SWOG Trial Support**

**Sponsor:** The Hope Foundation  
**Deadline:** Continuous  

“SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation. STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.”


**Therapeutic Development Initiative (TDI) – Funding for High-Impact Pediatric Cancer Research**

**Sponsor:** Solving Kids’ Cancer  
**Deadline:** Continuous  

“The Therapeutic Development Initiative (TDI) is SKC's strategic platform for the implementation of its research agenda as well as the vehicle for reviewing and prioritizing submitted research proposals. The TDI's goal is to support innovative clinical studies that are high on the risk/reward spectrum while, at the same time, investigating these research questions efficiently and effectively. Priority is given to proposals that introduce therapeutic agents and modalities which are first-in-children and have a strong potential to improve treatment outcomes. The TDI of SKC only supports clinical research. The organization specifically focuses on novel clinical studies for neuroblastoma, brain tumors and sarcomas.”


**Travel Grants: AACR Scholar-in-Training Awards – Other Conferences and Meetings**

**Sponsor:** AACR  
**Deadline:** Continuous  

“The AACR offers Scholar-in-Training Awards to enhance the education and training of early career scientists by providing financial support for their attendance at AACR conferences and meetings. These awards are provided to offset a portion of the registration, travel, and subsistence expenses incurred in attending these programs. Application requirements vary by conference.”